Amedisys (AMED) Tops Q1 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amedisys Reports First Quarter 2018 Financial Results and Reaffirms 2018 Guidance
May 7, 2018 5:00 PM EDTBATON ROUGE, La., May 07, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three month period ended March 31, 2018.
Three Month Periods Ended March 31, 2018 and 2017
Net service revenue increased $34.6 million to $399.3 million compared to $364.7 million in 2017(1).Net income attributable to Amedisys, Inc. of $27.2 million compared to $15.1 million in 2017.Net income attributable to Amedisys, Inc. per diluted share of $0.79 compared to $0.44 in 2017.Adjusted Quarterly Results*
Adjusted EBITDA of $41.7 million compared to $32.0 million in 2017.Adjusted net income attributable to Amedisys, Inc. of $27.3 million... More